Actinium Pharmaceuticals, Inc. (ATNM)

Both yoy net incomes decline, with AVXL at -15.11%. Martin Whitman would view it as a broader sector or cyclical slump hitting profits.

D&A growth of 3.01% while AVXL is zero at 0.00%. Bruce Berkowitz would see a mild cost difference that must be justified by expansions.

Well above AVXL's 144.12% if positive yoy. Michael Burry would see a risk of bigger working capital demands vs. competitor, harming free cash flow.

AP growth well above AVXL's 8.56%. Michael Burry would be concerned about potential late payments or short-term liquidity strain relative to competitor.

Growth well above AVXL's 314.25%. Michael Burry would see a potential hidden liquidity or overhead issue overshadowing competitor's approach.

Well above AVXL's 2.50%. Michael Burry would worry about large intangible write-downs or revaluation gains overshadowing real performance.

CapEx growth of 100.00% while AVXL is zero at 0.00%. Bruce Berkowitz would see a mild cost burden that must yield returns in future revenue or margins.

No Data available this quarter, please select a different quarter.

We expand invests by 100.00% while AVXL is zero at 0.00%. Bruce Berkowitz sees a moderate outflow that must be justified by returns vs. competitor’s stable approach.

We cut debt repayment yoy while AVXL is 0.00%. Joel Greenblatt sees competitor possibly lowering risk more if expansions do not hamper them.

Both yoy lines negative, with AVXL at -100.00%. Martin Whitman suspects an environment or preference for internal financing over new equity in the niche.

No Data available this quarter, please select a different quarter.